Literature DB >> 16815871

A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.

Xiao-Xia Yang1, Ze-Ping Hu, An-Long Xu, Wei Duan, Yi-Zhun Zhu, Min Huang, Fwu-Shan Sheu, Qiang Zhang, Jin-Song Bian, Eli Chan, Xiaotian Li, Jian-Cheng Wang, Shu-Feng Zhou.   

Abstract

Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin) (CPT-11)-based chemotherapy. A recent pilot study indicates that thalidomide attenuates the toxicity of CPT-11 in cancer patients. This study aimed to investigate whether coadministered thalidomide modulated the toxicities of CPT-11 and the underlying mechanisms using several in vivo and in vitro models. Diarrhea, intestinal lesions, cytokine expression, and intestinal epithelial apoptosis were monitored. Coadministered thalidomide (100 mg/kg i.p. for 8 days) significantly attenuated body weight loss, myelosuppression, diarrhea, and intestinal histological lesions caused by CPT-11 (60 mg/kg i.v. for 4 days). This was accompanied by inhibition of tumor necrosis factor-alpha, interleukins 1 and 6 and interferon-gamma, and intestinal epithelial apoptosis. Coadministered thalidomide also significantly increased the systemic exposure of CPT-11 but decreased that of SN-38 (7-ethyl-10-hydroxycampothecin). It significantly reduced the biliary excretion and cecal exposure of CPT-11, SN-38, and SN-38 glucuronide. Thalidomide hydrolytic products inhibited hydrolysis of CPT-11 in rat liver microsomes but not in primary rat hepatocytes. In addition, thalidomide and its major hydrolytic products, such as phthaloyl glutamic acid (PGA), increased the intracellular accumulation of CPT-11 and SN-38 in primary rat hepatocytes. They also significantly decreased the transport of CPT-11 and SN-38 in Caco-2 and parental MDCKII cells. Thalidomide and PGA also significantly inhibited P-glycoprotein (PgP/MDR1), multidrug resistance-associated protein (MRP1)- and MRP2-mediated CPT-11 and SN-38 transport in MDCKII cells. These results provide insights into the pharmacodynamic and pharmacokinetic mechanisms for the protective effects of thalidomide against CPT-11-induced intestinal toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815871     DOI: 10.1124/jpet.106.103606

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

Authors:  Jacqueline Ramírez; Kehua Wu; Linda Janisch; Theodore Karrison; Larry K House; Federico Innocenti; Ezra E W Cohen; Mark J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  2011-08-23       Impact factor: 3.333

2.  Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.

Authors:  Alina Shapira; Yehuda G Assaraf; Dikla Epstein; Yoav D Livney
Journal:  Pharm Res       Date:  2010-08-12       Impact factor: 4.200

Review 3.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

Review 4.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  Pharmacokinetics and tissue disposition of lenalidomide in mice.

Authors:  Darlene M Rozewski; Sarah E M Herman; William H Towns; Emilia Mahoney; Matthew R Stefanovski; Jungook D Shin; Xiaoxia Yang; Yue Gao; Xiaobai Li; David Jarjoura; John C Byrd; Amy J Johnson; Mitch A Phelps
Journal:  AAPS J       Date:  2012-09-07       Impact factor: 4.009

6.  A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

Authors:  Annabelle Ballesta; Sandrine Dulong; Chadi Abbara; Boris Cohen; Alper Okyar; Jean Clairambault; Francis Levi
Journal:  PLoS Comput Biol       Date:  2011-09-08       Impact factor: 4.475

7.  HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.

Authors:  Xu Wang; Dong-Ni Cui; Xiao-Min Dai; Jing Wang; Wei Zhang; Zun-Jian Zhang; Feng-Guo Xu
Journal:  Front Pharmacol       Date:  2017-03-30       Impact factor: 5.810

8.  A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor.

Authors:  Qi Zhang; Ting Deng; Fen Yang; Weijian Guo; Dan Liu; Jiajia Yuan; Changsong Qi; Yanshuo Cao; Qiuqiong Yu; Huiming Cai; Zhi Peng; Xicheng Wang; Jun Zhou; Ming Lu; Jifang Gong; Jian Li; Yi Ba; Lin Shen
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

9.  Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.

Authors:  Xiaoxi B Lin; Levinus A Dieleman; Ali Ketabi; Ilona Bibova; Michael B Sawyer; Hongyu Xue; Catherine J Field; Vickie E Baracos; Michael G Gänzle
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.